SAN DIEGO, May 14, 2015 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") will hold is 2015 Annual General Meeting of Stockholders (the "AGM") on Wednesday, May 27, 2015 at 5:30 p.m. PDT (which is 10:30 a.m. on Thursday, 28 May 2015, AEST). The meeting will be held at the AGL Theatre in the Museum of Sydney located at the corner of Phillip and Bridge Streets in Sydney, Australia.
The AGM will be audiocast and may be accessed within the United States and Canada by dialing Australia by dialing 1-877-312-5413 five minutes prior to the scheduled start time. Callers Australia may access the call by dialing (02) 8223 9773. If you are asked to provide an access code, please spell out the word "REVA" to the operator and you will be connected promptly.
If you reside outside of the United States, Canada, or Australia, or if you prefer to access the audiocast through our website, please visit "Events & Presentations" under the "Investors" section of our website at www.revamedical.com, and click on the "listen to webcast" link. A replay of the audiocast will be available on our website after the call.
About REVA
REVA is a development stage medical device company located in San Diego, California, USA, that is focused on the development, testing, and eventual commercialization of its proprietary bioresorbable stents, which are called "scaffolds" because of their temporary nature. The Company's scaffolds are currently in clinical studies and have been developed as an alternative to metal stents, which are small tube-like devices permanently implanted into an artery to treat coronary artery disease. Scaffolds provide restoration of blood flow, support the artery through the healing process, then disappear (or "resorb") from the body over a period of time. This resorption allows the return of natural movement and function of the artery, a result not attainable with permanent metal stents. The Company's initial intended commercial product, the FantomTM scaffold, has been designed to offer an ideal balance of thinness and strength, and distinct ease-of-use features including complete scaffold visibility under x-ray, expansion with one continuous inflation, and no procedural time limitations. REVA will require successful clinical trial results and regulatory approval before it can commercialize Fantom or any other products.